CN107001251A - 双(磺酰胺)衍生物及其作为mpges抑制剂的用途 - Google Patents
双(磺酰胺)衍生物及其作为mpges抑制剂的用途 Download PDFInfo
- Publication number
- CN107001251A CN107001251A CN201580064771.XA CN201580064771A CN107001251A CN 107001251 A CN107001251 A CN 107001251A CN 201580064771 A CN201580064771 A CN 201580064771A CN 107001251 A CN107001251 A CN 107001251A
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyl
- formula
- chloro
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VUTNKSAUAHXYRT-UHFFFAOYSA-N CC(C(C1c(cccc2)c2NS(CCc(c(OCCc2cccc(C#N)c2)c2)ccc2Cl)(=O)=O)N)C1=O Chemical compound CC(C(C1c(cccc2)c2NS(CCc(c(OCCc2cccc(C#N)c2)c2)ccc2Cl)(=O)=O)N)C1=O VUTNKSAUAHXYRT-UHFFFAOYSA-N 0.000 description 1
- MEWNVJTXPIUAOE-UHFFFAOYSA-N CC(C)(C)[SiH-](C)(C)Oc1c(CBr)ccc(Cl)c1 Chemical compound CC(C)(C)[SiH-](C)(C)Oc1c(CBr)ccc(Cl)c1 MEWNVJTXPIUAOE-UHFFFAOYSA-N 0.000 description 1
- SYBOHXSUNQQXJF-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)Oc1c(C=O)ccc(Cl)c1 Chemical compound CC(C)(C)[Si](C)(C)Oc1c(C=O)ccc(Cl)c1 SYBOHXSUNQQXJF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451434-3 | 2014-11-27 | ||
| SE1451434 | 2014-11-27 | ||
| PCT/SE2015/051261 WO2016085391A1 (en) | 2014-11-27 | 2015-11-24 | Bis(sulfonamide) derivatives and their use as mpges inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107001251A true CN107001251A (zh) | 2017-08-01 |
Family
ID=56074770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580064771.XA Pending CN107001251A (zh) | 2014-11-27 | 2015-11-24 | 双(磺酰胺)衍生物及其作为mpges抑制剂的用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10227296B2 (https=) |
| EP (1) | EP3224241A4 (https=) |
| JP (1) | JP2017537157A (https=) |
| CN (1) | CN107001251A (https=) |
| WO (1) | WO2016085391A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000024T1 (it) * | 2014-11-27 | 2020-03-13 | Gesynta Pharma Ab | Derivati di bis (solfonammide) e loro uso come inibitori di mpges |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250818A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Inc | Ortho substituted aryl or heteroaryl amide compounds |
| US20090131468A1 (en) * | 2007-11-15 | 2009-05-21 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy 065 |
| US20100292279A1 (en) * | 2009-05-14 | 2010-11-18 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy |
| CN101945859A (zh) * | 2007-12-20 | 2011-01-12 | 阿斯利康(瑞典)有限公司 | 用于治疗的二(磺酰基氨基)衍生物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| CN101284773A (zh) * | 2001-08-09 | 2008-10-15 | 小野药品工业株式会社 | 羧酸衍生物及以它为活性成分的药剂 |
| CA2620363A1 (en) | 2005-10-13 | 2007-04-19 | Biolipox Ab | Naphthalene-disulfonamides useful for the treatment of inflammation |
| WO2008129276A1 (en) | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
| WO2008129288A2 (en) | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| CA2747835A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2015
- 2015-11-24 WO PCT/SE2015/051261 patent/WO2016085391A1/en not_active Ceased
- 2015-11-24 CN CN201580064771.XA patent/CN107001251A/zh active Pending
- 2015-11-24 JP JP2017547370A patent/JP2017537157A/ja active Pending
- 2015-11-24 EP EP15863225.7A patent/EP3224241A4/en not_active Withdrawn
- 2015-11-24 US US15/529,701 patent/US10227296B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250818A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Inc | Ortho substituted aryl or heteroaryl amide compounds |
| US20090131468A1 (en) * | 2007-11-15 | 2009-05-21 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy 065 |
| CN101945859A (zh) * | 2007-12-20 | 2011-01-12 | 阿斯利康(瑞典)有限公司 | 用于治疗的二(磺酰基氨基)衍生物 |
| US20100292279A1 (en) * | 2009-05-14 | 2010-11-18 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180002278A1 (en) | 2018-01-04 |
| JP2017537157A (ja) | 2017-12-14 |
| WO2016085391A1 (en) | 2016-06-02 |
| EP3224241A4 (en) | 2018-08-08 |
| EP3224241A1 (en) | 2017-10-04 |
| US10227296B2 (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105828820B (zh) | 布罗莫结构域抑制剂 | |
| JP5869740B2 (ja) | Gabaa受容体モジュレーターとしてのイミダゾピリダジン誘導体 | |
| ES2532357T3 (es) | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor | |
| TWI546289B (zh) | 嗒酮化合物及其作為d-胺基酸氧化酶酵素(daao)抑制劑之用途 | |
| CN112218857B (zh) | P300/cbp hat抑制剂及其使用方法 | |
| CN101160285A (zh) | 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物 | |
| WO2023084158A1 (en) | Cyp11a1 inhibitors | |
| TW201022283A (en) | Fused imidazole carboxamides as TRPV3 modulators | |
| CN101506181B (zh) | 三环化合物及其制药用途 | |
| CN101622233A (zh) | 三环化合物及其药物用途 | |
| CN101687810A (zh) | 双环化合物及其药物用途 | |
| EP3131893B1 (en) | Polycyclic herg activators | |
| ES2278980T3 (es) | Derivados de 4'-metanosulfonil-bifenilo como un inhibidor muy selectivo de ciclooxigenasa-2. | |
| US6809204B2 (en) | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | |
| CN107001251A (zh) | 双(磺酰胺)衍生物及其作为mpges抑制剂的用途 | |
| ES2349066T3 (es) | Compuestos de piridilmetilbiciclocarboxamida sustituida. | |
| JP6649538B2 (ja) | ビス(スルホンアミド)誘導体およびmPGES阻害薬としてのその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20200310 |
|
| AD01 | Patent right deemed abandoned |